Publications

April 2019

A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, & Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Feb 2019

Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.

Mar 2016

Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines.

Feb 2016

Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications.

Oct 2015

Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.

SEPT 2015

Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs.

Feb 2015

Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).

July 2014

Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response.

May 2014

Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia.

Jan 2014

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.

Jan 2014

Mcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response.

Dec 2013

BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia.

Nov 2013

Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker.

July 2005

Effects of Bcl-2 levels on Fas signaling-induced caspase-3 activation: molecular genetic tests of computational model predictions.